March 5, 2018 04:10 PM EST

Cambridge star Magenta teams up with Heidelberg on bone marrow R&D pact that includes $334M in potential milestones

Brittany Meiling

High-flying Cambridge upstart Magenta Therapeutic has inked an exclusive deal with a German biotech to work on drugs that might improve bone marrow transplants for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Cambridge star Magenta teams up with Heidelberg on bone marrow R&D pact that includes $334M in potential milestones

Brittany Meiling

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Cam­bridge star Ma­gen­ta teams up with Hei­del­berg on bone mar­row R&D pact that in­cludes $334M in po­ten­tial mile­stones

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Cambridge star Magenta teams up with Heidelberg on bone marrow R&D pact that includes $334M in potential milestones